HomeARWR • NASDAQ
Arrowhead Pharmaceuticals Inc
$28.14
After Hours:
$28.14
(0.00%)0.00
Closed: Mar 18, 4:28:36 PM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed securityUS headquartered
Previous close
$28.28
Day range
$27.21 - $28.36
Year range
$20.67 - $42.48
Market cap
3.49B USD
Avg Volume
1.71M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD)Dec 2023Y/Y change
Revenue
3.55M-94.32%
Operating expense
140.10M33.83%
Net income
-132.86M-221.51%
Net profit margin
-3.74K-5,563.07%
Earnings per share
-1.24-217.95%
EBITDA
-132.28M-235.36%
Effective tax rate
2.39%
Total assets
Total liabilities
(USD)Dec 2023Y/Y change
Cash and short-term investments
213.38M-56.85%
Total assets
626.29M-29.75%
Total liabilities
452.57M-8.59%
Total equity
173.71M
Shares outstanding
123.90M
Price to book
18.98
Return on assets
-49.05%
Return on capital
-55.21%
Net change in cash
(USD)Dec 2023Y/Y change
Net income
-132.86M-221.51%
Cash from operations
-117.84M-56.05%
Cash from investing
64.84M180.35%
Cash from financing
267.00K-99.89%
Net change in cash
-52.68M-155.89%
Free cash flow
-168.71M-59.25%
About
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. The company has sixteen products in its pipeline, in various stages of development. In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis. In April 2016, it was announced that the former company name, Arrowhead Research Corporation, will be changed to Arrowhead Pharmaceuticals, Inc. In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease. On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. Wikipedia
Founded
1989
Employees
525
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu